Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp
Share on telegram
Share on email

No se encontraron resultados

La página solicitada no pudo encontrarse. Trate de perfeccionar su búsqueda o utilice la navegación para localizar la entrada.

prueba

Empagliflozina

Sacubitrilo Valsartán
Docherty PARADIGM HF2
PARADIGM-HF
PARAGON HF
PIONEER HF
TITRATION
TRANSITION Study
Kidney Outcomes: ARNI vs. ACE Inhibitors

Diabetes

Diabetic Agents, From Metformin
EMPA KIDNEY
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Empare reduced en español JACC
EMPULSE
Gliflozins From Antidiabetic Drugs to Cornerstone in Heart
Safety of Empagliflozin in
SGLT2 Inhibitors Statins or ACE Inhibitors of the 21st Century
SGLT2 Inhibitors the Statins of the 21st Century
The EMPEROR Reduced Trial
The role of SGLT2 I in vascular aging

Insuficiencia Cardiaca

2022 AHA ACC HFSA Guideline for ICC resumen
Guía ESC 2021 Full text
Guía manejo ICC AHA full text
Iacoviello – Recent advances in pharmacological treatment of heart failure
ADA 2023 Pharmacologic Approaches
Docherty PARADIGM HF2
PARADIGM-HF
PARADIGM-HF

Enfermedad Renal

Cardiorenal Syndrome Classification Pathophysiology Diagnosis and Treatment Strategies A Scientific Statement From the American Heart Association
KDIGO 2022
Management of Heart Failure in Patients with Chronic Kidney Disease
Synopsis KDIGO 2022
Use of Glucose Lowering Agents
Docherty PARADIGM HF2
PARADIGM-HF
PARAGON HF
PIONEER HF
TITRATION
TRANSITION Study
Kidney Outcomes: ARNI vs. ACE Inhibitors